Maravai LifeSciences Holdings, Inc. Class A Common Stock MRVI
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T14:56:44.548Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:56:36.62585529Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T14:56:43.206093+00:00
Maravai LifeSciences Holdings, Inc. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 9.79 | 109.8% | 28.5% | 7.55 | 107.5% | 16.6% |
| 40Δ | 9.43 | 120.1% | 26.8% | 7.94 | 107.8% | 14.9% |
| 45Δ | 9.06 | 130.4% | 25.1% | 8.33 | 108.2% | 13.2% |
| 50Δ | 8.69 | 140.6% | 23.4% | 8.73 | 108.6% | 11.6% |
| 55Δ | 8.33 | 150.9% | 21.6% | 9.12 | 108.9% | 9.9% |
| 60Δ | 7.96 | 161.2% | 19.9% | 9.51 | 109.3% | 8.2% |
| 65Δ | 7.60 | 171.4% | 18.2% | 9.90 | 109.7% | 6.5% |
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 9.79
- IV
- 109.8%
- B/E move
- 28.5%
- Pseudo strike
- 7.55
- IV
- 107.5%
- B/E move
- 16.6%
40Δ
- Pseudo strike
- 9.43
- IV
- 120.1%
- B/E move
- 26.8%
- Pseudo strike
- 7.94
- IV
- 107.8%
- B/E move
- 14.9%
45Δ
- Pseudo strike
- 9.06
- IV
- 130.4%
- B/E move
- 25.1%
- Pseudo strike
- 8.33
- IV
- 108.2%
- B/E move
- 13.2%
50Δ
- Pseudo strike
- 8.69
- IV
- 140.6%
- B/E move
- 23.4%
- Pseudo strike
- 8.73
- IV
- 108.6%
- B/E move
- 11.6%
55Δ
- Pseudo strike
- 8.33
- IV
- 150.9%
- B/E move
- 21.6%
- Pseudo strike
- 9.12
- IV
- 108.9%
- B/E move
- 9.9%
60Δ
- Pseudo strike
- 7.96
- IV
- 161.2%
- B/E move
- 19.9%
- Pseudo strike
- 9.51
- IV
- 109.3%
- B/E move
- 8.2%
65Δ
- Pseudo strike
- 7.60
- IV
- 171.4%
- B/E move
- 18.2%
- Pseudo strike
- 9.90
- IV
- 109.7%
- B/E move
- 6.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 123.08% | |
| 126.06% | |
| 123.24% |
Biotechnology
NAMS
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its…
More →NAUT
Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is…
More →NBTX
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
More →NGNE
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical…
More →NKTR
Description unavailable
More →NKTX
Description unavailable
More →